Welcome to our dedicated page for Rocket Doctor AI news (Ticker: AIRDF), a resource for investors and traders seeking the latest updates and insights on Rocket Doctor AI stock.
Rocket Doctor AI Inc. (AIRDF) is a healthcare technology company that reports on developments at the intersection of artificial intelligence and digital health. Company news frequently highlights its physician-built Global Library of Medicine (GLM), an AI-powered clinical decision support system, and the activities of its wholly owned digital health platform and marketplace, Rocket Doctor Inc.
Investors and observers following AIRDF news can read about partnerships, technology rollouts, and corporate milestones. Recent announcements have covered collaborations with organizations such as the CAN Health Network and Health Cities in Alberta to pilot an AI-powered Clinical Decision Support System, as well as a strategic partnership between Rocket Doctor Inc. and Toronto Metropolitan University to expand clinical education opportunities on a digital health platform. The company also publishes updates on its U.S. expansion, including payer credentialing and leadership appointments to support growth across multiple states.
Rocket Doctor AI’s news flow includes information on product development, such as enhancements to its GLM, Starship EMR, RD Connect, and RD Health Voyager tools, along with initiatives like pharmacy-based virtual care programs and emergency department diversion efforts. Corporate and capital markets updates, including private placements, analyst coverage arrangements, and grants of restricted share units and stock options, are also disclosed through news releases.
This news page aggregates these company-issued updates in one place, allowing readers to follow how Rocket Doctor AI is applying AI-powered clinical decision support, virtual care technology, and partnerships with healthcare and academic institutions. For those tracking AIRDF, the news feed provides context on how the company describes its strategy, technology evolution, and market initiatives over time.
Rocket Doctor AI (OTC:AIRDF) reported Q3 2025 results showing continued sequential organic revenue growth and operational milestones. Revenue for Q3 2025 was $529,123 (up from $512,756 in Q2 2025 and $10,990 in Q3 2024). Gross margin was 88%. The company reported a net comprehensive loss of $3.5 million or $0.05 per share and Adjusted EBITDA loss of $1.8 million. Cash and equivalents improved to $1.89 million after an oversubscribed financing raising C$4.23 million. Corporate progress includes U.S. in‑network payer agreements extending reach to >13 million insured members and an NIH SBIR award of up to $500,000 USD for Treatment USA.
Rocket Doctor AI (OTC: AIRDF) announced that CEO Dr. Bill Cherniak spoke at the Google Accelerator Alumni Summit in Mexico City and presented at Heal.LA Accelerator Demo Day on Nov 26, 2025. As the only healthcare founder invited to speak, he discussed Rocket Doctor’s journey and the company's use of Google Gemini conversational models in its AI Nurse platform. Rocket Doctor AI says it is exploring expanded capabilities after the recent Gemini 3.0 launch and highlighted ongoing integration with Google Cloud and its proprietary Global Library of Medicine (GLM). The company remains focused on scaling clinically aligned AI tools and access to care into 2026.
Rocket Doctor AI (OTC: AIRDF) entered a definitive agreement to acquire 100% of Alea Health Holdings Ltd. on November 19, 2025. Consideration includes US$15,000 cash paid, 285,712 common shares (deemed CAD$0.70 each) and assumption of a US$180,000 SAFE note payable in US$22,500 monthly instalments. Alea’s conversational AI and voice-based mental‑health platform will be integrated with Rocket Doctor AI’s Global Library of Medicine to expand mental‑health capabilities and enter the UAE/GCC market.
Closing is subject to employment agreements, regulatory approvals including the CSE, and applicable shareholder approvals; securities will be issued under prospectus exemptions with hold periods and a 28‑month escrow schedule.
Rocket Doctor AI (OTC:AIRDF) granted an aggregate 831,356 restricted share units (RSUs) and 20,964 stock options to consultants and employees on Nov 7, 2025.
The Options are exercisable for one common share at an exercise price of C$0.82 per share for a three‑year term and are subject to vesting provisions and plan terms.
- RSU terms: 325,000 RSUs expire in two years; 506,356 RSUs expire in three years.
- Vesting: 203,000 RSUs vest immediately; 628,356 RSUs are subject to vesting provisions.
- All grants are subject to the company equity plans and applicable securities law hold periods.
Rocket Doctor (OTC:AIRDF) on Nov 5, 2025 announced four senior U.S. appointments to accelerate clinical operations, digital growth, and coast‑to‑coast expansion. New hires include Dr. Evan Ou as U.S. Medical Director, Dr. Sudha Kumar as U.S. MD Lead for Psychiatry, Dr. Mike Solemar as California MD Lead, and Jimmy Vannavong as Director of Growth. The hires target strengthened payer and community partnerships, expanded provider networks in key states, and data‑driven patient recruitment via AI-enabled marketing. The move follows recent payer credentialing in New York and California and aims to improve access in rural and underserved U.S. communities.
Rocket Doctor AI (OTC:AIRDF) announced engagement of Fundamental Research Corp for independent analyst coverage effective Oct 21, 2025.
FRC is described as a long‑standing independent small‑cap research firm with a 22‑year track record and coverage of 750+ companies; its reports are distributed via Reuters, Capital IQ, Bloomberg and by subscription.
Under the agreement FRC will deliver a full financial analysis including an Independent Analyst Rating, an initiating report, periodic updates and unlimited interim notes over an 18‑month term. The company paid FRC a fee of CAD$35,000 in connection with the engagement.
Rocket Doctor (OTC:AIRDF) announced on October 21, 2025 that its Rocket Doctor platform is now in-network with two additional U.S. payers, expanding coverage by approximately 6.5 million members across California and New York.
The agreements (signed on October 9 and 10, 2025) add ~2.7 million covered lives in California and ~3.8 million in New York, bringing Rocket Doctor’s total in-network reach to well over 13 million members. The contracts span commercial, Medicare Advantage, and Veterans coverage and aim to broaden access to AI-powered, physician-led primary, urgent, chronic and mental healthcare.
Rocket Doctor AI (OTC:AIRDF) engaged FN Media Group for a three-day news and digital media marketing campaign starting the week of October 20, 2025 for USD $14,085.
FN Media will use its proprietary traffic application plus Google/Yahoo digital ads. The firm and its directors do not own any interest in Rocket Doctor AI and are described as arm’s length. FN Media contact details and address are provided in the announcement.
Rocket Doctor AI (OTC: AIRDF) announced that its U.S. subsidiary Treatment.com, together with Rush River Research, received a US $2.0 million NIH SBIR Phase II grant awarded by the National Institute on Minority Health and Health Disparities.
The two-year award advances an AI-powered, culturally sensitive family medical history tool, provides Treatment with over $500,000 to enhance its Global Library of Medicine (GLM), and supports commercialization and integration across commercial platforms with usability and community testing focused initially on African-American communities.
Rocket Doctor AI (OTCQB: AIRDF), a healthcare technology company, will present at the 2025 CANTech Letter Conference in Toronto on October 9, 2025. CEO Dr. Essam Hamza and Rocket Doctor Inc. Founder Dr. William Cherniak will deliver their presentation at 2:30 PM ET in Track 1.
The presentation will showcase the company's AI-powered healthcare platform, which focuses on improving healthcare accessibility and patient outcomes through streamlined workflows and reduced administrative friction. The company's leadership will discuss their platform innovations, recent milestones, and growth strategy.